Scripps Led Team Awarded $22.5 Million for Immune Response Project
News Aug 30, 2012
The grant is focused on innovative technologies that will ultimately provide data for improving a wide range of human diseases that include viral and bacterial infections and inherited immune disorders.
"I’m delighted the National Institute of Allergy and Infectious Diseases has decided to continue supporting this important research," said the grant’s principal investigator Richard Ulevitch, who is a professor and chairman emeritus at Scripps Research. “Since the initiative began 10 years ago, the consortium has made seminal contributions to the field. Now, thanks to the new funding, there are more discoveries to come.”
The project takes an unusual wide-angle “genetic and systems biology” approach to learning how we stay healthy in the face of numerous microbes in our environment. In contrast to traditional hypothesis-driven research, in which a single gene or protein is selected for study based on its proposed function, team members assemble information about multiple genes, proteins, and biochemical pathways without preconceived ideas about function. This data is then integrated and examined from multiple perspectives to understand the immune response as a whole.
In addition to Ulevitch and his group at Scripps Research, the consortium includes the laboratories of Alan Aderem of the Seattle Biomedical Research Institute, Bruce Beutler of University of Texas Southwestern Medical Center, Christopher Goodnow of the Australian National University, and Garry Nolan of Stanford University.
Ulevitch notes that the group is now especially interested in the intersection between innate and adaptive immunity. Innate immunity, our body's first line of defense, can destroy foreign invaders and trigger inflammation that contributes to their demise. If microorganisms make it past this gauntlet, the body calls on adaptive immunity. Here, T cells, B cells, antibodies, and killer cells come into play; the adaptive immune system also stores "memories" of the offending microorganisms to be on the alert for future attacks.
The team is using a genetic approach in mice, known as “forward genetics,” to develop a detailed model of innate and adaptive immune responses to infection. “It is now crystal clear that data from mouse genetics provides insights into human disease,” Ulevitch said. “When we started there were a lot more unknowns, but now there is a long list of genes identified in the mouse that cause both specific mouse phenotypes and are similarly linked to human disease.”
The group provides resources to the scientific community at large, including a Web-based data portal to access the team’s findings (see www.systemsimmunology.org).
This program has received ongoing support from NIH since 2002. The NIH project number for the grant is U19 AI100627.
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Way Found to Boost Immunity in Fighting Cancer and InfectionsNews
Researchers have identified a key new mechanism that regulates the ability of T-cells of the immune system to react against foreign antigens and cancer.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018